» Articles » PMID: 36692803

Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness

Overview
Journal Dig Dis Sci
Specialty Gastroenterology
Date 2023 Jan 24
PMID 36692803
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Cardiorespiratory fitness and liver fibrosis are independently associated with poor outcomes in patients with nonalcoholic steatohepatitis (NASH), however, conflicting reports exist about their relationship. We aimed to better characterize the relationship between cardiorespiratory fitness and liver histology in a cross-sectional study of patients with biopsy-proven NASH.

Methods: Participants aged 18-75 years completed VO fitness assessment using symptom-limited graded exercise testing. Participants were compared by liver fibrosis stage and NAFLD Activity Score (NAS). Multivariable models were constructed to assess factors related to relative VO, including liver fibrosis and NAS.

Results: Thirty-five participants with mean age 48 ± 12 years and body mass index 33.5 ± 7.6 kg/m were enrolled. Seventy-four percent of participants were female and 49% had diabetes. A dose-dependent relationship was found between relative VO and liver fibrosis. Relative VO was significantly lower in participants with advanced fibrosis (F3 disease- 15.7 ± 5.3 vs. ≤ F2 disease- 20.7 ± 5.9 mL/kg/min, p = 0.027). NAS > 5 was also associated with lower relative VO (22.6 ± 5.7 vs. 16.5 ± 5.1 mL/kg/min, p = 0.012) compared to NAS ≤ 5. With multivariable modeling, advanced fibrosis remained independently predictive of relative VO while NAS trended towards significance.

Discussion And Conclusions: Advanced liver fibrosis is independently associated with cardiorespiratory fitness in patients with NASH. This may explain the incremental increase in mortality as liver fibrosis stage increases. Further research is needed to determine if exercise training can improve cardiorespiratory fitness across multiple stages of liver fibrosis and directly reduce morbidity and mortality in patients with NASH.

Citing Articles

AMPED study: Protocol for a randomized controlled trial of different doses of aerobic exercise training.

Stine J, Hummer B, Smith N, Tressler H, Heinle J, VanKirk K Hepatol Commun. 2024; 8(7).

PMID: 38896071 PMC: 11186820. DOI: 10.1097/HC9.0000000000000464.


Untangling frailty, sarcopenia, and physical fitness in cirrhosis.

Duarte-Rojo A, Bux R, Sliwa J Clin Liver Dis (Hoboken). 2024; 23(1):e0213.

PMID: 38841195 PMC: 11152786. DOI: 10.1097/CLD.0000000000000213.


Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective.

Keating S, Chawla Y, De A, George E Hepatol Int. 2024; 18(Suppl 2):959-976.

PMID: 38717691 PMC: 11450077. DOI: 10.1007/s12072-024-10663-9.


Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms.

Heinle J, DiJoseph K, Sabag A, Oh S, Kimball S, Keating S Nutrients. 2023; 15(11).

PMID: 37299416 PMC: 10255270. DOI: 10.3390/nu15112452.


Physical Activity and Nonalcoholic Fatty Liver Disease: A Roundtable Statement from the American College of Sports Medicine.

Stine J, Long M, Corey K, Sallis R, Allen A, Armstrong M Med Sci Sports Exerc. 2023; 55(9):1717-1726.

PMID: 37126039 PMC: 10524517. DOI: 10.1249/MSS.0000000000003199.


References
1.
Angulo P, Kleiner D, Dam-Larsen S, Adams L, Bjornsson E, Charatcharoenwitthaya P . Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015; 149(2):389-97.e10. PMC: 4516664. DOI: 10.1053/j.gastro.2015.04.043. View

2.
Bowden Davies K, Pickles S, Sprung V, Kemp G, Alam U, Moore D . Reduced physical activity in young and older adults: metabolic and musculoskeletal implications. Ther Adv Endocrinol Metab. 2019; 10:2042018819888824. PMC: 6878603. DOI: 10.1177/2042018819888824. View

4.
Dulai P, Singh S, Patel J, Soni M, Prokop L, Younossi Z . Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017; 65(5):1557-1565. PMC: 5397356. DOI: 10.1002/hep.29085. View

5.
Loomba R, Lim J, Patton H, El-Serag H . AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2020; 158(6):1822-1830. PMC: 8012107. DOI: 10.1053/j.gastro.2019.12.053. View

6.
Ekstedt M, Franzen L, Mathiesen U, Thorelius L, Holmqvist M, Bodemar G . Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44(4):865-73. DOI: 10.1002/hep.21327. View